[{"id":"c9d1a579-ede0-4060-a970-738063622323","acronym":"","url":"https://clinicaltrials.gov/study/NCT03654716","created_at":"2021-01-18T17:56:08.387Z","updated_at":"2025-02-25T14:40:01.342Z","phase":"Phase 1","brief_title":"Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer","source_id_and_acronym":"NCT03654716","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" TP53 • MDM2 • TET2 • SMARCB1 • PPM1D","pipe":" | ","alterations":" TP53 wild-type • TET2 mutation","tags":["TP53 • MDM2 • TET2 • SMARCB1 • PPM1D"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • TET2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 21","initiation":"Initiation: 11/01/2018","start_date":" 11/01/2018","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 07/17/2023","study_completion_date":" 07/17/2023","last_update_posted":"2025-02-14"},{"id":"8626d796-d31d-4f11-a4ab-8ea3dce4cf77","acronym":"","url":"https://clinicaltrials.gov/study/NCT03725436","created_at":"2021-01-18T18:15:21.875Z","updated_at":"2024-07-02T16:35:08.781Z","phase":"Phase 1","brief_title":"ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors","source_id_and_acronym":"NCT03725436","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A","pipe":" | ","alterations":" ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification","tags":["HER-2 • ER • TP53 • MDM2 • MDM4 • GDF15 • CASP3 • CDKN1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • TP53 wild-type • MDM4 amplification • MDM2 mutation • TP53 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • sulanemadlin (ALRN-6924)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 35","initiation":"Initiation: 01/24/2019","start_date":" 01/24/2019","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2024-04-18"},{"id":"592b7eaa-b0b9-44ec-a9e0-7a40a914198a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02264613","created_at":"2021-01-18T10:39:31.889Z","updated_at":"2024-07-02T16:36:43.300Z","phase":"Phase 1/2","brief_title":"ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas","source_id_and_acronym":"NCT02264613","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53 • MDM2 • CDK4","pipe":" | ","alterations":" TP53 wild-type • MDM2 amplification • CDK4 amplification","tags":["TP53 • MDM2 • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type • MDM2 amplification • CDK4 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 149","initiation":"Initiation: 10/01/2014","start_date":" 10/01/2014","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 04/01/2020","study_completion_date":" 04/01/2020","last_update_posted":"2020-07-14"},{"id":"b98cd67d-2012-4eee-853b-5c1f66a8faed","acronym":"","url":"https://clinicaltrials.gov/study/NCT02909972","created_at":"2021-01-18T14:16:56.352Z","updated_at":"2024-07-02T16:36:53.442Z","phase":"Phase 1","brief_title":"Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome","source_id_and_acronym":"NCT02909972","lead_sponsor":"Aileron Therapeutics, Inc.","biomarkers":" TP53","pipe":" | ","alterations":" TP53 wild-type","tags":["TP53"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cytarabine • sulanemadlin (ALRN-6924)"],"overall_status":"Completed","enrollment":" Enrollment 55","initiation":"Initiation: 09/01/2016","start_date":" 09/01/2016","primary_txt":" Primary completion: 04/01/2019","primary_completion_date":" 04/01/2019","study_txt":" Completion: 08/01/2019","study_completion_date":" 08/01/2019","last_update_posted":"2019-11-19"}]